ORA:EURONEXT PARISOrange SA Analysis
Data as of 2026-03-10 - not real-time
$109.85
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Ormat Technologies (ORA) trades at a price well above its DCF‑derived fair value of roughly $75 and carries a trailing P/E of 54× versus an industry average of 21×, indicating the stock is currently overvalued. The company posted solid revenue growth of nearly 20% YoY and maintains a modest dividend yield of 0.44% with a payout ratio under 25%, yet free cash flow remains negative and leverage is high (debt‑to‑equity >100%). Technicals show a neutral trend: the 20‑day SMA sits above the current price, the MACD histogram is bearish and RSI hovers around 42, while volume is increasing. Recent news is mixed – a Jefferies downgrade to “Hold” tempers sentiment, but a new 150 MW geothermal PPA with Google adds a positive catalyst.
Overall, the valuation gap and elevated risk metrics suggest caution in the near term, but the company’s growth trajectory in renewable power and strategic contracts could support a longer‑term upside if execution improves and cash generation turns positive.
Overall, the valuation gap and elevated risk metrics suggest caution in the near term, but the company’s growth trajectory in renewable power and strategic contracts could support a longer‑term upside if execution improves and cash generation turns positive.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD histogram and price below the 20‑day SMA
- Jefferies downgrade to Hold
- Increasing volume but price near recent support
Medium Term
1–3 yearsCautious
Model confidence: 5/10
Key Factors
- Significant overvaluation relative to DCF and peers
- Negative free cash flow and high leverage
- Potential price correction toward fair value
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong revenue growth and expanding renewable portfolio
- Strategic 150 MW geothermal PPA with Google
- Long‑term upside from global clean‑energy demand
Key Metrics & Analysis
Financial Health
Revenue Growth19.60%
Profit Margin12.52%
P/E Ratio54.4
ROE4.84%
ROA1.75%
Debt/Equity106.16
P/B Ratio2.6
Op. Cash Flow$335.1M
Free Cash Flow$-291521248
Industry P/E20.8
Technical Analysis
TrendNeutral
RSI42.0
Support$100.84
Resistance$127.79
MA 20$114.77
MA 50$117.70
MA 200$101.08
MACDBearish
VolumeIncreasing
Fear & Greed Index77.57
Valuation
Fair Value$74.90
Target Price$128.00
Upside/Downside16.52%
GradeOvervalued
TypeGrowth
Dividend Yield0.44%
Risk Assessment
Beta0.58
Volatility43.22%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.